Nephronophthisis 15 (NPHP15) Cell Models for Research

Nephronophthisis 15 (NPHP15) is a rare autosomal recessive ciliopathy caused by mutations in CEP164. It is a major genetic cause of end-stage renal disease (ESRD) in children and young adults. The exact incidence is unknown, but nephronophthisis overall affects approximately 1 in 50,000 to 1 in 100,000 individuals. NPHP15 is characterized by chronic tubulointerstitial nephritis, leading to progressive renal failure. Patients typically present with polyuria, polydipsia, and secondary enuresis, and progress to ESRD within the first two decades of life. Extrarenal manifestations include retinal degeneration, cerebellar vermis hypoplasia, and liver fibrosis. The disease has a significant impact on quality of life and requires renal replacement therapy. Early diagnosis and genetic testing are crucial for management and family counseling.

NPHP15 is an excellent model for studying ciliary function, DNA damage response, and renal fibrosis. The disease is monogenic, making it amenable to gene editing. Research focuses on understanding the molecular mechanisms of CEP164 in ciliogenesis and its role in cell cycle regulation. Gene-edited cell models, such as CEP164 knockout or knock-in lines, are valuable tools for dissecting these pathways. Public datasets, including ClinVar and gnomAD, provide mutation information, while DepMap offers functional dependency data. Open questions include the precise role of CEP164 in DNA damage repair and how specific mutations lead to variable clinical phenotypes.

Although NPHP15 is not a cancer, the underlying pathways are relevant to tumorigenesis. CEP164 is involved in the DNA damage response (DDR) and ciliary signaling. Key pathways include:

• • DNA damage response: CEP164 is a substrate of ATM/ATR kinases and is required for efficient checkpoint activation after DNA damage.
• • Ciliary signaling: CEP164 is essential for ciliogenesis and ciliary trafficking, affecting Hedgehog and Wnt signaling.
• • Cell cycle regulation: CEP164 interacts with the centrosome and regulates G2/M transition.

Dysregulation of these pathways can lead to genomic instability and abnormal proliferation, contributing to cancer development.

Data from ClinVar and gnomAD. In cancer, CEP164 alterations are rare but have been reported in renal cell carcinoma and other tumors, suggesting a potential tumor suppressor role.

CEP164 dysfunction affects multiple signaling networks:

• • DNA damage response: Defective activation of ATM/ATR, leading to genomic instability.
• • Ciliary signaling: Impaired Hedgehog signaling, affecting tissue patterning.
• • Wnt signaling: Altered canonical and non-canonical Wnt pathways, contributing to renal fibrosis.
• • Cell cycle: Dysregulation of G2/M checkpoint, promoting proliferation.

Key nodes include ATM, ATR, CHK1, CHK2, and ciliary proteins such as IFT88.

Organoids derived from patient iPSCs can recapitulate renal tubule structure and are useful for studying ciliary function and drug responses.

• • Cep164 knockout mice: Show embryonic lethality, indicating essential role.
• • Conditional knockout mice: Tissue-specific deletion in renal tubules leads to cyst formation and fibrosis.
• • Zebrafish models: Morpholino knockdown of cep164 causes renal cysts and ciliary defects.
• • Patient-derived xenografts (PDX): Not commonly used for NPHP15, but renal cell carcinoma PDX models may have CEP164 mutations.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific CEP164 mutations. For example:

• • CEP164 knockout cell lines: Complete loss of function, useful for studying null phenotypes.
• • CEP164 knock-in cell lines: Introduction of patient-specific point mutations (e.g., p.Arg708Trp) to model hypomorphic alleles.

These models are commercially available from sources that provide sequence-verified, clonally derived cell lines. They are essential for functional studies, drug screening, and validating therapeutic targets. Using isogenic pairs (wild-type vs. mutant) eliminates genetic background variability, enabling precise attribution of phenotypes.

Gene-edited cell lines allow functional validation of CEP164 variants. For example:

• • Knockout lines: Demonstrate loss of cilia and impaired DNA damage response.
• • Knock-in lines: Assess the impact of specific mutations on protein function.

These models help identify novel interaction partners and downstream effectors through proteomics and transcriptomics.

Isogenic cell line pairs are ideal for high-throughput screening. For instance:

• • Screen compounds that rescue ciliary defects in CEP164 knockout cells.
• • Test drugs that modulate DNA damage response in mutant cells.
• • Assess resistance to chemotherapeutic agents in CEP164-mutant cancer cells.

CRISPR-based synthetic lethality screens can identify vulnerabilities in CEP164-deficient cells. For example:

• • Knockout CEP164 in a renal cell line and screen for genes whose depletion is lethal.
• • Identify biomarkers of disease progression by comparing transcriptomes of wild-type and mutant cells.